135 related articles for article (PubMed ID: 38357930)
1. Targeting de novo lipogenesis to mitigate kidney disease.
Li H; Humphreys BD
J Clin Invest; 2024 Feb; 134(4):. PubMed ID: 38357930
[TBL] [Abstract][Full Text] [Related]
2. ACSS2 gene variants determine kidney disease risk by controlling de novo lipogenesis in kidney tubules.
Mukhi D; Li L; Liu H; Doke T; Kolligundla LP; Ha E; Kloetzer K; Abedini A; Mukherjee S; Wu J; Dhillon P; Hu H; Guan D; Funai K; Uehara K; Titchenell PM; Baur JA; Wellen KE; Susztak K
J Clin Invest; 2023 Dec; 134(4):. PubMed ID: 38051585
[TBL] [Abstract][Full Text] [Related]
3. Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver.
Steensels S; Qiao J; Zhang Y; Maner-Smith KM; Kika N; Holman CD; Corey KE; Bracken WC; Ortlund EA; Ersoy BA
Hepatology; 2020 Sep; 72(3):857-872. PubMed ID: 32498134
[TBL] [Abstract][Full Text] [Related]
4. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK
J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.
Stiede K; Miao W; Blanchette HS; Beysen C; Harriman G; Harwood HJ; Kelley H; Kapeller R; Schmalbach T; Westlin WF
Hepatology; 2017 Aug; 66(2):324-334. PubMed ID: 28470676
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ACSS2 attenuates alcoholic liver steatosis via epigenetically regulating de novo lipogenesis.
Lu Y; Chen Y; Hu W; Wang M; Wen X; Yang J
Liver Int; 2023 Aug; 43(8):1729-1740. PubMed ID: 37183518
[TBL] [Abstract][Full Text] [Related]
7. Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet.
Ye L; Cao Z; Lai X; Shi Y; Zhou N
J Nutr; 2020 Apr; 150(4):672-684. PubMed ID: 31858105
[TBL] [Abstract][Full Text] [Related]
8. Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1/AMPK/PP2A Axis.
Gnoni A; Di Chiara Stanca B; Giannotti L; Gnoni GV; Siculella L; Damiano F
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162967
[TBL] [Abstract][Full Text] [Related]
9. Fructose drives de novo lipogenesis affecting metabolic health.
Geidl-Flueck B; Gerber PA
J Endocrinol; 2023 May; 257(2):. PubMed ID: 36753292
[TBL] [Abstract][Full Text] [Related]
10. Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice.
Cordoba-Chacon J; Majumdar N; List EO; Diaz-Ruiz A; Frank SJ; Manzano A; Bartrons R; Puchowicz M; Kopchick JJ; Kineman RD
Diabetes; 2015 Sep; 64(9):3093-103. PubMed ID: 26015548
[TBL] [Abstract][Full Text] [Related]
11. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y
Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159
[TBL] [Abstract][Full Text] [Related]
12. Persistent fasting lipogenesis links impaired ketogenesis with citrate synthesis in humans with nonalcoholic fatty liver.
Fu X; Fletcher JA; Deja S; Inigo-Vollmer M; Burgess SC; Browning JD
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36928190
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease.
Paglialunga S; Dehn CA
Lipids Health Dis; 2016 Sep; 15(1):159. PubMed ID: 27640119
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
[TBL] [Abstract][Full Text] [Related]
15. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
[TBL] [Abstract][Full Text] [Related]
16. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
[TBL] [Abstract][Full Text] [Related]
17. The hepatocyte IKK:NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis.
Heida A; Gruben N; Catrysse L; Koehorst M; Koster M; Kloosterhuis NJ; Gerding A; Havinga R; Bloks VW; Bongiovanni L; Wolters JC; van Dijk T; van Loo G; de Bruin A; Kuipers F; Koonen DPY; van de Sluis B
Mol Metab; 2021 Dec; 54():101349. PubMed ID: 34626855
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
Beysen C; Schroeder P; Wu E; Brevard J; Ribadeneira M; Lu W; Dole K; O'Reilly T; Morrow L; Hompesch M; Hellerstein MK; Li K; Johansson L; Kelly PF
Diabetes Obes Metab; 2021 Mar; 23(3):700-710. PubMed ID: 33289350
[TBL] [Abstract][Full Text] [Related]
19. MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies.
Nagarajan SR; Livingstone EJ; Monfeuga T; Lewis LC; Ali SHL; Chandran A; Dearlove DJ; Neville MJ; Chen L; Maroteau C; Ruby MA; Hodson L
Metabolism; 2023 Jul; 144():155563. PubMed ID: 37088121
[TBL] [Abstract][Full Text] [Related]
20. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.
Lee JJ; Lambert JE; Hovhannisyan Y; Ramos-Roman MA; Trombold JR; Wagner DA; Parks EJ
Am J Clin Nutr; 2015 Jan; 101(1):34-43. PubMed ID: 25527748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
